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Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an
inherited vascular dementia characterized by the degeneration of smooth-muscle cells in small cerebral arteries.
CADASIL is caused by mutations in NOTCH3, one of the four mammalian homologs to the Drosophila melan-
ogaster NOTCH gene. Disease-associated mutations are distributed throughout the 34 epidermal growth factor–
like repeats (EGFRs) that compose the extracellular domain of the Notch3 receptor and result in a loss or a gain
of a cysteine residue in one of these EGFRs. In human adults, Notch3 expression is highly restricted to vascular
smooth-muscle cells. In patients with CADASIL, there is an abnormal accumulation of Notch3 in the vessel.
Molecular pathways linking NOTCH3 mutations to degeneration of vascular smooth-muscle cells are as yet poorly
understood. In this study, we investigated the effect of CADASIL mutations on Notch3 activity. We studied ﬁve
naturally occurring mutations: R90C and C212S, located in the previously identiﬁed mutational hotspot EGFR2–
5; C428S, shown in this study to be located in the ligand-binding domain EGFR10–11; and C542Y and R1006C,
located in EGFR13 and EGFR26, respectively. All ﬁve mutant proteins were correctly processed. The C428S and
C542Y mutant receptors exhibited a signiﬁcant reduction in Jagged1-induced transcriptional activity of a RBP/JK
responsive luciferase reporter, relative to wild-type Notch3. Impaired signaling activity of these two mutants arose
through different mechanisms; the C428S mutant lost its Jagged1-binding ability, whereas C542Y retained it but
exhibited an impaired presentation to the cell surface. In contrast, the R90C, C212S, and R1006C mutants retained
the ability to bind Jagged1 and were associated with apparently normal levels of signaling activity. We conclude
that mutations in Notch3 differently affect Jagged1 binding and Notch3 signaling via the RBP/JK pathway.
CADASIL (cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy)
(MIM 125310) is an adult-onset disorder characterized
by recurrent ischemic strokes, dementia, and premature
death (Tournier-Lasserve et al. 1993; Chabriat et al.
1995; Dichgans et al. 1998). The pathological hallmark
is a systemic nonamyloid and nonatherosclerotic vas-
culopathy, which affects predominantly the small cere-
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bral arteries. Vessel changes are characterized by pro-
gressive degeneration of smooth-muscle cells, as well as
by the accumulation, in the vessel wall, of an unknown
material that appears by electronmicroscopy as granular
osmiophilic material (GOM) (Baudrimont et al. 1993;
Ruchoux et al. 1995).
CADASIL is caused by mutations in Notch3, a mem-
ber of the highly conserved Notch transmembrane re-
ceptors family (Joutel et al. 1996). NOTCH3 (MIM
600276) encodes a single-pass transmembrane receptor
with a large extracellular domain containing 34 tandem
epidermal growth factor–like repeats (EGFRs). Notch3,
initially synthesized as a ∼280-kDa precursor, undergoes
proteolytic processing like the other Notch receptors.
This results in the formation of a mature heterodimeric
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transmembrane receptor, consisting of a 210-kDa extra-
cellular domain (Notch3ECD) that is noncovalently at-
tached to a 97-kDa transmembrane/cytosolic fragment
(Notch3TMIC) (Joutel et al. 2000a). Notch receptors are
activated by members of the Delta/Jagged transmem-
brane ligands family (Artavanis-Tsakonas et al. 1999).
In response to ligand binding, Notch receptors undergo
sequential proteolytic cleavages, producing the active
Notch intracellular domain that forms a complex with
the transcription factor RBP/JK (De Strooper et al. 1999;
Brou et al. 2000; Mumm et al. 2000). This complex
regulates the transcription of downstream genes and
modulates numerous cell fate decisions during devel-
opment (Artavanis-Tsakonas et al. 1999). So far, the
precise function of Notch3 in human adult tissues has
not been elucidated.
NOTCH3 mutations in patients are distributed
throughout the 34 EGFRs and include essentially single
amino acid substitutions. Mutations are highly stereo-
typed, leading to the addition or the loss of a cysteine
residue and, therefore, to an EGFR with an odd number
of cysteine residues (Joutel et al. 1997; Oberstein et al.
1999; Dichgans et al. 2000; Joutel et al. 2000b; Markus
et al. 2002). EGFR2–5, which have no predicted func-
tional role, have been identiﬁed as forming a mutational
hotspot (Joutel et al. 1997). We and others have recently
identiﬁed pathogenic mutations in EGFR10 and EGFR11
that are predicted to be required for ligand binding, by
homology to theDrosophilamelanogasterNotchreceptor
(Rebay et al. 1991; Lawrence et al. 2000; Arboleda-Ve-
lasquez et al. 2002; Markus et al. 2002; A.J., F.R., and
E.T.-L., unpublished data).
We recently demonstrated that vascular smooth-mus-
cle cells are the primary targets of the pathogenic pro-
cess. In normal human adults, expression of Notch3 is
highly restricted to these cells. In patients with CA-
DASIL, there is an abnormal accumulation of the
Notch3 extracellular domain (ECD) that takes place at
the plasma membrane of vascular smooth-muscle cells
(Joutel et al. 2000a). However, the molecular pathways
linking Notch3 mutations to degeneration of vascular
smooth-muscle cells are poorly understood. Different
hypotheses have been proposed. First, the pathogenic
effect of mutations may result from a primary signaling
defect of mutated receptors. Two studies have shown
that four different Notch3 mutants retained the ability
to interact with soluble Delta1, and one mutant ap-
peared not to affect signaling mediated by Jagged1 or
Delta1 (Haritunians et al. 2002; Karlstrom et al. 2002).
Another hypothesis is that accumulation of the Notch3
ECD may dominantly inhibit the normal Notch3 path-
way through competitive inhibition of ligand binding or
ligand sequestering. Finally, it has been proposed that
excess Notch3 or GOM deposits may be toxic for vas-
cular smooth-muscle cells, by analogy with several other
progressive adult-onset neurologic diseases in which ab-
normal protein accumulation has been recurrently dem-
onstrated and is suspected to play a major role in path-
ogenesis (Spinner 2000). We recently observed that
vascular smooth-muscle cell defects precede Notch3 ac-
cumulation and GOM deposits in transgenic mice mim-
icking CADASIL arteriopathy (Ruchoux et al. 2003).
These ﬁndings did not support the two latest hypotheses,
prompting us to further investigate the possibility that
mutant Notch3 receptors may exhibit an impaired sig-
naling activity.
In the present study, we investigated ﬁve naturally
occurring NOTCH3 mutations for their ability to
transduce ligand-mediated signaling: two mutations lo-
cated in the mutational hotspot region, one mutation
lying in a region that we showed in this study to be
required for ligand binding and signaling activity, and
two mutations located in other EGFRs. Below, we dem-
onstrate that two of these ﬁve mutations result in im-
paired ligand-induced Notch3 activity, mediated by the
RBP/JK transcription factor through different molec-
ular mechanisms, whereas three other mutations ap-
pear to retain normal activity.
We ﬁrst assessed the requirement of EGFR10 and
EGFR11 of Notch3 for ligand binding and signaling
activity. Using a PCR-based approach with wild-type
Notch3 as a template, we made a Notch3 construct
lacking the 78-aa coding sequence of EGFR10–11
(Notch3DEGF10-11). Immunoblot analysis of lysates from
293T cells and NIH3T3 cells transiently transfectedwith
the wild-type or Notch3DEGF10-11 construct revealed that
both proteins were correctly processed, generating the
210-kDa ECD and the 97-kDa transmembrane intra-
cellular (TMIC) fragments that use, respectively, the 5E1
monoclonal antibody to the ECD (ﬁg. 1A) and the bc4
polyclonal antibody to the intracellular domain (data
not shown). We further examined whether wild-type and
Notch3DEGF10-11 receptors correctly reached the cell sur-
face in 293T cells and NIH3T3 cells. Transiently trans-
fected cells were treated with NHS-SS-biotin and were
subsequently lysed and immunoprecipitated with im-
mobilized streptavidin. Immunoblot analysis showed that
the 97-kDa TMIC and the 210-kDa ECD fragments, but
not the 280-kDa full-length receptor, were detected at the
cell surface. Moreover, the relative amounts of cell-sur-
face–expressed receptors did not differ between wild-type
Notch3 (ﬁg. 1) and Notch3DEGF10-11–expressing cells. As a
potential relevant ligand of Notch3, we focused on Jag-
ged1 for the following reasons: (1) of the ﬁve known
Delta/Jagged ligands, Delta4, Jagged1, and Jagged2 have
been shown to be expressed in the vessel during devel-
opment; (2) Delta4 and Jagged2 appear to be expressed
in endothelial cells and Jagged1 in both endothelial and
smooth-muscle cells (Villa et al. 2001); and (3) we found
that, in human adults, Jagged1 was coexpressed with
Figure 1 EGFR10 and 11 of Notch3 are required for Jagged1 binding and Jagged1-stimulated transcriptional activity of RBP/JK. A,
Protein extracts of 293T cells were transiently transfected with either wild-type Notch3 (N3WT), empty vector (vector), or Notch3 construct
lacking EGFR10–11 (N3DEGFR10–11). These extracts were analyzed by western blot by use of the bc4 a-Notch3IC polyclonal antibody,
revealing both the 280-kDa full-length unprocessed (FL) and the processed 97-kDa TMIC proteins in N3WT- and N3DEGFR10–11-expressing
cells. B, Cell surface proteins of 293T cells (left panel) or NIH3T3 cells (right panel) transiently transfected with either wild-type Notch3
(N3WT) or Notch3 construct lacking EGFR10–11 (N3DEGFR10–11). The proteins were biotinylated using NHS-SS-biotin. Cells were lysed
in RIPA buffer, and extracts were loaded on a 6% SDS-PAGE gel, either directly (T fraction, 2.5% and 1.7% of the extract from 293T cells
and NIH3T3 cells, respectively) or after incubation on streptavidin-agarose beads (B fraction, 81% and 63% of the extract from 293T cells
and NIH3T3 cells, respectively). Extracts were then immunoblotted with the bc4 a-Notch3IC antibody (left panel) or the 5E1 a-Notch3ECD
antibody (right panel). Positions of the 280-kDa full-length unprocessed (FL) and the processed 97-kDa (TMIC) and 210-kDa (ECD) proteins
are indicated. Note that only the processed proteins, but not the full-length precursor, were detected at the cell surface. The ratio between the
biotinylated receptor (B) and the total amount of expressed receptor (T) did not differ between N3WT and N3DEGFR10–11. The asterisk in
the right panel marks a band that likely corresponds to crossreacting material because it was detected in the B fraction of cells transfected with
an unrelated construct (data not shown). C, Transfected cells, incubated with conditioned medium containing sJ1-Fc preclustered using the
FITC-conjugated goat anti-human Fc antibody (1:100 dilution) (Jackson ImmunoResearch). After incubation with preclustered conditioned
medium, cells were washed with PBS, ﬁxed with paraformaldehyde 3%, and immunostained using the 1E4 a-Notch3ECD monoclonal antibody
(1:5 dilution) without prior permeabilization and a Texas Red–conjugated goat anti-mouse antibody (1:100 dilution) (Jackson ImmunoResearch).
Red ﬂuorescence detected Notch3, and green ﬂuorescence identiﬁed binding of sJ1-Fc to the Notch3-expressing cells. Both wild-type and
DEGFR10–11 Notch3 proteins were detected at the cell surface (C.a and C.c). Binding of sJ1-Fc was detected to wild-type Notch3-expressing
cells (C.b) but not to DEGFR10–11-Notch3–expressing cells (C.d). The immunoﬂuorescence is one representative experiment (original mag-
niﬁcation # 40). D, NIH3T3 cells transiently cotransfected with either wild-type Notch3 (N3WT), psG5 empty vector (vector), or Notch3
construct lacking EGFR10–11 (N3DEGFR10–11), as well as the RBP/JK reporter and the SV40-lacZ control plasmid, were cocultured with
either Jagged1-expressing cells (J1) or the parental cells (L) and assayed for luciferase activity. The activity measured was expressed as relative
luciferase units (RLU), which reﬂect the fold increase relative to the activity detected with NIH3T3 cells transfected with the psg5 empty vector
cocultured with L cells; the results are the mean SEM from six independent experiments performed in triplicate. Jagged1 induced signiﬁcant
RBP/JK activation in the N3WT cells (compare 14.5 3.1 RLU [N3WT J1] and 2.2 0.3 RLU [vector J1], ) and was signiﬁcantlyPp .006
reduced in the N3DEGFR10–11 cells (7.2  2.7 RLU; versus N3WT  J1).Pp .004
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Notch3 in vascular smooth-muscle cells (data not
shown). To assess for Jagged1 binding, we used a soluble
form of Jagged1 that contained only the ECD (aa 1–
990) fused in frame with a human IgG Fc sequence (sJ1-
Fc) in a ligand-binding assay, as described elsewhere
(Hicks et al. 2000). (The Jagged1 cDNA sequence is
available on the National Center for Biotechnology In-
formation Web site.) A conditioned medium containing
sJ1-Fc was prepared by transient transfection of the sJ1-
Fc construct into 293T cells, and the sJ1-Fc amount was
quantiﬁed by western blot analysis with a horseradish
peroxidase–conjugated anti-Fc antibody and a known
quantity of puriﬁed human IgG1. The 293T cells, tran-
siently transfected with either wild-type Notch3,
Notch3DEGFR10-11 constructs, or the empty vector, were
incubated with a sJ1-Fc–conditioned medium that was
preclustered with a ﬂuorescein isothiocyanate (FITC)–
conjugated anti-Fc antibody. Notch3-expressing cells
were detected using the 1E4 monoclonal antibody to the
ECD, and immunostaining without prior cell permea-
bilization further showed that both wild-type Notch3
and Notch3DEGFR10-11 were correctly targeted to the cell
surface (ﬁg. 1C, left column, red ﬂuorescence). The bind-
ing of sJ1-Fc was detected using the FITC ﬂuorescence
intrinsic to the Fc-clustering antibody (ﬁg. 1C, right col-
umn, green ﬂuorescence). sJ1-Fc binding was detected
in wild-type Notch3-expressing cells but not in
Notch3DEGF10-11-expressing cells. Moreover, sJI-Fc was
not detected in Notch3-expressing cells in the absence
of sJ1-Fc preclustering, nor in Notch3-expressing cells
incubated with a preclustered control-conditioned me-
dium supplemented with puriﬁed IgG1 immunoglobulin
(data not shown).
Previous studies have shown that, using a coculture
assay of Notch- and ligand-expressing cells, Notch sig-
naling resulted in stimulation of transcriptional activity
of RBP/JK (Hicks et al. 2000). To assess for Jagged1-
induced signaling activity, NIH3T3 cells growing in 100-
mm dishes were transfected with 3.5 mg of either the
wild-type Notch3 construct, the Notch3DEGFR10-11, or the
psg5 empty vector, together with 1 mg of the SV40-lacZ
control plasmid and 2 mg of the pGa981-6 luciferase
construct, containing the hexamerized RBP/JK-respon-
sive element. The ﬁnal quantity of total plasmid DNA,
which was transfected, was adjusted to 10 mg with the
psg5 plasmid. NIH3T3 transfected cells were then
spread over murine Jagged1-expressing cells or the LTK
parental cells and were grown in 35-mm dishes. Lucif-
erase activities were measured ∼30 h after coculture and
were normalized by the LacZ activities in each sample.
As shown in ﬁgure 1D, Jagged1 signiﬁcantly activated
RBP/JK in cells expressing wild-type Notch3 but failed
to activate RBP/JK in cells expressing Notch3DEGFR10-11.
Together, these data indicate that EGFR10–11 of
Notch3 are required for Jagged1 binding and Jagged1-
induced signaling.
Next, we examined the ability of naturally occurring
mutations to transduce Jagged1-induced signaling. We
generated ﬁve Notch3 mutant constructs, representa-
tive of the mutations detected in an extended series of
patients characterized in our department (A.J., F.R.,
and E.T.-L., unpublished data). This included two mu-
tations located in the mutational hotspot region (i.e.,
R90C in EGFR2 and C212S in EGFR5), one mutation
located in the ligand-binding domain (C428S in
EGFR10), and two mutations located in other EGFRs
(C542Y in EGFR13 and R1006C in EGFR26) (ﬁg. 2A).
The R90C and C212S mutants were generated by PCR,
by use of mutated oligonucleotides and wild-type
Notch3 as a template. The C428S, C542Y, and
R1006C mutants were made by site-directed mutagen-
esis, by use of appropriate oligonucleotides containing
a single-nucleotide substitution. Mutant constructs
were expressed in 293T and NIH3T3 cells by transient
transfection. Immunoblot analysis demonstrated that
all mutant proteins were correctly processed, generat-
ing the 210-kDa Notch3ECD (ﬁg. 2B) and the 97-kDa
Notch3TMIC (data not shown).
We then assessed Jagged1-induced RBP/JK transcrip-
tional activities mediated by the mutant receptors.
NIH3T3 cells were transfected with 3.5 mg of either the
wild-type Notch3 construct, the mutant constructs, or
the psg5 empty vector, together with 2 mg of the RBP/
JK-luciferase reporter, 1 mg of the SV40-lacZ control
plasmid, and the ﬁnal quantity of plasmid DNA, which
was adjusted to 10 mg with the psg5 plasmid. NIH3T3
cells were cocultured with Jagged1-expressing cells or
parental ﬁbroblast cells and assayed for luciferase activ-
ity, as described above. As shown in ﬁgure 2C, Jagged1-
mediated activation of RBP/JK was not signiﬁcantly dif-
ferent between wild-type Notch3-expressing cells and
either R90C, C212S, or R1006C mutant Notch3-ex-
pressing cells. In contrast, transcriptional activity was
signiﬁcantly reduced in cells expressing C428S orC542Y
mutant Notch3. Because all NOTCH3 mutations in CA-
DASIL, except one, are heterozygous mutations, we ex-
amined the effects of Notch3 mutants on the activity of
the wild-type Notch3 (Tuominen et al. 2001). Simulated
heterozygous states were obtained by cotransfecting
equal amounts of wild-type (1.75 mg) and mutant (1.75
mg) constructs, and the amount of wild-typeNotch3 con-
struct in the wild-type Notch3 control was increased (3.5
mg) to make it comparable to the doubly transfected
cells. Results showed no difference for the R90Cmutant,
which, at the homozygous state, did not affect ligand-
induced signaling and showed intermediate behavior for
both the C428S and C542Y mutants (table 1). These
data indicate that the C428S and C542Y mutants dem-
onstrate a signiﬁcant reduction in Jagged1-induced RBP/
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Figure 2 Effect of mutations on RBP/JK transcriptional activity induced by Jagged1. A, Schematic diagram of the Notch3 proteins. The
missense mutants used in this study are denoted by bars beneath the diagram; numbers indicate amino acid positions. The S1 cleavage site is
depicted; TM, transmembrane domain. B, NIH3T3 cells, transiently transfected with either wild-type Notch3 (WT), empty vector (vector), or
mutated Notch3 constructs (R90C, C212S, C428S, C542Y, and R1006C). Extracts were immunoblotted with the a-Notch3 ECD antibody
5E1, revealing both the 280-kDa full-length unprocessed (FL) and the processed 210-kDa Notch3ECD (ECD) proteins. The ratio between the
210-kDa processed form and the 280-kDa full-length unprocessed protein are almost identical between the wild-type and the mutant Notch3
receptors. C, NIH3T3 cells, transiently cotransfected with the RBP/JK luciferase reporter and plasmids encoding either wild-type Notch3 (WT),
empty vector (vector), or Notch3 constructs carrying the indicated point mutations, cocultured with either Jagged1-expressing cells (J1) or
parental cells (L), and assayed for luciferase activity, as described above. The activity measured was expressed as relative luciferase units (RLU),
which reﬂect the fold increase relative to the activity detected with NIH3T3 cells transfected with the psG5 empty vector cocultured with L
cells; results are the mean SEM from ﬁve independent experiments performed in triplicate. Jagged1 activation of RBP/JK was not signiﬁcantly
affected by the R90C (16.5  3.0 RLU), C212S (15.3  3.1 RLU), and R1006C mutations (11.4  1.4 RLU) when compared with WT-
Notch3 (13.8  2.3 RLU) but was signiﬁcantly reduced by the C428S (6.1  0.9 RLU) and C542Y mutations (5.4 0.4 RLU) ( forPp .02
both mutants versus N3WT  Jagged1).
JK transcriptional activity, whereas the other three mu-
tants appear to maintain normal activity.
We further examined the mechanisms for impaired
signaling of the C428S and C542Y mutants. We ﬁrst
analyzed mutant receptors for cell surface expression by
using the 1E4 monoclonal antibody raised against the
Notch3 ECD to immunostain unpermeabilized cells. The
C428S and C542Y mutant proteins were detected at the
cell surface, as were the wild-type receptor and the three
other mutant proteins, R90C, C212S, and R1006C (ﬁg.
3A, red ﬂuorescence). We showed above that mutant
receptors were correctly processed. However, examina-
tion of total Notch3 levels in the cells is not necessarily
representative of what is making it to the cell surface.
Moreover, the immunoﬂuorescence assay described
above did not provide a precise estimate of the number
of receptors expressed at the cell surface. Therefore, we
further analyzed whether mutant receptors were cor-
rectly presented at the cell surface by biotinylation ex-
periments, as described above. Experiments were per-
formed in NIH3T3 cells that were used for signaling.
Immunoblot analysis with the 5E1 antibody to the ECD
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Table 1
Comparison of Jagged1-Induced RBP/JK Activity in Cells Expressing
either Wild-Type Notch3, Mutant Notch3, or Simulated
Heterozygous Notch3 Mutants
Type of Cell
% of Relative Activity
Induced by Jagged1a
P Values versus
WT-Notch3
WT 100 …
R90C 79.7  13.8 NSb
R90C  WT 99.0  23.8 NSb
C428S 18.0  11.2 !.001
C428S  WT 59.7  10.6 !.01
C542Y 30.0  6.8 !.001
C542Y  WT 62.3  11.7 !.01
a Jagged1-induced activation was expressed as the ratio of nor-
malized luciferase value induced by Jagged1-expressing cells compared
with that obtained with parental L cells; relative activity reﬂects ac-
tivation induced by Jagged1, relative to that obtained with wild-type
Notch3. The mean SEM data from three independent experiments
performed in triplicate are presented.
b NS p not signiﬁcant.
showed that only the 210-kDa ECD fragment, but not
the 280-kDa full-length precursor, was detected at the
cell surface for all ﬁve mutants (ﬁg. 3B). The C542Y
mutant exhibited a 5.4-fold decrease (mean value) in the
relative amount of ECD detected at the cell surface, rel-
ative to wild-type Notch3. In contrast, the relative
amounts of cell surface expression of the four other mu-
tants, including C428S, were almost comparable to
those of wild-type Notch3 (three independent experi-
ments) (ﬁg. 3B). These data indicate that all ﬁve mutant
receptors reach the cell surface in the cleaved form, and
the C542Y mutant, but not the other mutants, exhibits
signiﬁcantly fewer receptors at the cell surface. We then
assayed mutant receptors for their ability to interactwith
Jagged1, through the use of the ligand-binding assay
described above. Cells expressing the C428S mutant did
not bind preclustered sJ1-Fc. In contrast, all other mu-
tant-expressing cells, including those expressing the
C542Y mutant, bound preclustered sJ1-Fc at a level
comparable to that detected for the wild-type receptor
(ﬁg. 3A, green ﬂuorescence). Together, these data suggest
that the signaling defect of the C428S mutant likely
arises from its loss of ligand-binding ability, but that of
the C542Y mutant arises from a different mechanism
that might involve an impaired presentation of the re-
ceptor to the cell surface.
In this study, we investigated the biological activities of
ﬁve naturally occurring NOTCH3 mutations represen-
tative of those detected in a large series of patients with
CADASIL. Herein, we demonstrate for the ﬁrst time, to
our knowledge, (1) that EGFR10 and EGFR11 ofNotch3
are required for ligand binding and signaling activity, (2)
that CADASIL-associated mutations may impair or not
Notch3 receptor signaling via the RBP/JK pathway, and
(3) that CADASIL can be caused by a Notch3 mutant
that has lost its ability to interact with the ligand.
Of the ﬁve mutants analyzed, C428S and C542Y ex-
hibit a signiﬁcant reduction in Jagged1-induced tran-
scriptional activity of a RBP/JK-responsive luciferase re-
porter. Our data suggest that the impaired activity of
these two mutants arises through different mechanisms.
The mutations C428S and C542Y are located in and
around, respectively, the ligand-binding domain. The
C428S mutation appears to impair neither receptormat-
uration nor its trafﬁcking but results in a loss of Jagged1-
binding ability, whereas the C542Y mutation appears to
retain the ability to bind Jagged1 but results in an im-
proper presentation of the receptor to the cell surface,
with fewer cleaved receptors reaching the cell surface.
Whether decreased signaling activity of the C542Y mu-
tant arises from this trafﬁcking defect is uncertain. In-
deed, the mutant murine Notch3 carrying the R142C
mutation has been recently reported to exhibit an im-
paired S1 proteolytic cleavage, resulting in a strong re-
duction of cell surface expression but normal ligand-
induced signaling (Karlstrom et al. 2002). Several lines
of evidence indicate the important role of the EGF re-
peats in modulating activity of the receptor (Okajima
and Irvine 2002; Li et al. 2003). Therefore, an alternative
cause for the signaling defect of the C542Ymutantmight
be that EGFR13 of Notch3 is involved in such a role,
and the C542Y mutation impairs this function.
Our data indicate that distinct CADASIL mutations
have apparently different effects on Notch3 signaling via
the RBP/JK pathway. We show that two mutations result
in impaired activity of the receptor, whereas three others
appear to have no effect. How can these data be rec-
onciled with the highly stereotyped nature of CADASIL
mutations? Different hypotheses may be raised. First, all
mutations may lead to abnormal receptor activity that
is mediated by the canonical RBP/JK signaling pathway,
but this abnormality cannot be detected for some mu-
tations by use of the in vitro assay employed in this study.
There is evidence from several studies that the activity
of Notch receptors is submitted to a tight regulation that
is highly dependent on the cell context (Okajima and
Irvine 2002; Li et al. 2003). Superimposed on the core
components, including the ligand, the receptor, and the
nuclear proteins that form a complex with the cleaved
intracellular domain of Notch, is a wide array of mod-
ulators (Justice and Jan 2002). This raises the possibility
that the effect of some mutations on the activity of the
receptor may become apparent only in the presence of
given modulators; such modulators might be not ex-
pressed in the cells employed in this study. Moreover,
modulators of the Notch3 receptor remain to be iden-
tiﬁed. Second, the pathogenicity of mutations may arise
through an impaired activity of the receptor that is not
mediated by the canonical RBP/JK signaling pathway.
Figure 3 Effect of mutations on cell surface expression and Jagged1-binding ability. A, 293T cells transiently transfected with wild-type
Notch3 or Notch3 constructs carrying the indicated point mutations. They were incubated with a preclustered conditioned medium containing
sJ1-Fc and then ﬁxed and immunostained using the 1E4 a-Notch3 ECD antibody, with no prior permeabilization, followed by a Texas Red–
conjugated secondary antibody. All ﬁve mutant proteins were detected at the cell membrane (A.c, A.e, A.g, A.i, A.k; red ﬂuorescence). The
binding of sJ1-Fc to the Notch3-expressing cells was detected by the FITC-conjugated clustering a-IgG antibody. sJ1-Fc did not bind to C428S
Notch3 mutant cells (A.h) but bound to all four other mutant-expressing cells (A.d, A.f, A.j, A.l; green ﬂuorescence). The immunoﬂuorescence
is one representative experiment (original magniﬁcation#40). B, Cell surface proteins of NIH3T3 cells transiently transfected with either wild-
type Notch3 (N3WT) or Notch3 constructs carrying the indicated point mutations. They were biotinylated using NHS-SS-biotin. Cells were
lysed in RIPA buffer, and extracts were loaded on a 6% SDS-PAGE gel either directly (T fraction, 1.7% of the extract) or after incubation on
streptavidin-agarose beads (B fraction, 63% of the extract). Extracts were then immunoblotted with the 5E1 a-Notch3ECD antibody. Positions
of the 280-kDa full-length unprocessed (FL) and the processed 210-kDa (ECD) proteins are indicated. Only the ECD protein, but not the full-
length precursor, was detected at the cell surface. The ratio between the biotinylated receptor (B) and the total amount of expressed receptor
(T) was lower for the C542Y mutant, compared with N3WT and the four other mutants. The western blot is from one representative experiment.
The asterisks mark a band that likely corresponds to crossreacting material because it was detected in the B fraction of cells transfected with
an unrelated construct (data not shown).
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In support of this second hypothesis are the recent re-
ports that Notch receptors can signal in RBP/JK-inde-
pendent modes (Shawber et al. 1996). Moreover, it has
been shown that the phenotype of some Drosophila mu-
tants, including the Abruptex mutant 59d carrying a
cysteine mutation in the EGFR24 of the Notch receptor,
is not dependent on Su(H) (the DrosophilaRBP/JK hom-
olog) function (Brennan et al. 1999). Finally, the path-
ogenicity of mutations may arise through a mechanism
unrelated to the activity of the receptor.
A previous study reported that the CADASIL mutation
R142C of murine Notch3, which corresponds to muta-
tion R141C in humans, impaired the S1 proteolytic cleav-
age (Karlstrom et al. 2002). None of the mutant receptors
investigated in our study appeared to exhibit such a defect.
Indeed, we found that the ratio between the processed
forms and the full-length unprocessed protein was almost
identical between the wild-type and the mutant Notch3
receptors in whole-cell extracts from both 293T cells and
NIH3T3 cells. However, these two studies were per-
formed with differently expressed Notch3 receptors (sta-
bly transfected cells in the previous study versus tran-
siently transfected cells in our study). So far, we do not
know whether the discrepancy in results may have arisen
from the differences in the two studies. We also observed
that, for a given Notch3 construct, including wild-type
Notch3, the ratio between the processed forms and the
full-length, unprocessed Notch3 protein could vary from
one experiment to another, depending on the total
Notch3 expression level. Moreover, it is important to
bear in mind that the full-length form is overrepresented
in transfected cells as compared with normal human
adult tissues, in which the unprocessed protein is almost
undetectable and the processed forms are expressed at
very low levels (Joutel et al. 2000a). These observations
suggest to us that both the cell type and the expression
level of Notch3 might affect the S1 processing efﬁciency
and that the S1 cleavage efﬁciency should be analyzed
with caution in cells overexpressing Notch3.
The mechanism of the selective Notch3ECD accumu-
lation in CADASIL, in the absence of an associated
Notch3TMIC accumulation, is not yet understood (Joutel
et al. 2000a). It has been proposed that Notch3ECD ac-
cumulation may occur during or after receptor activa-
tion, on the basis of the fact that, upon receptor acti-
vation, ECD and TMIC fragments of Notch dissociate
from each other through sequential proteolytical cleav-
ages (Fortini 2001). One prediction from this model is
that no or less Notch3ECD should accumulate in patients
carrying a Notch3 mutation abrogating ligand-binding
ability and, thus, receptor activation. We recently had
the opportunity to perform Notch3 immunostaining of
vessels from patients carrying either a mutation shown
in this study to abolish ligand-binding ability, such as
the C428S mutation, or a mutation that seems to affect
neither ligand binding nor signaling activity, such as the
R90C or the C21S mutations. Notch3ECD accumulation
was detected in all these patients (Joutel et al. 2001). It
is important to note that the amount of Notch3ECD was
found to be almost identical between the C428S mu-
tation carriers and the R90C or C212S mutation carriers
(data not shown). Therefore, our results indicate that
Jagged1 binding is not a prerequisite for Notch3ECD ac-
cumulation in patients. It remains to be determined
whether a mutation abrogating binding to Jagged1 could
abrogate binding to any other Delta/Jagged1 ligands; the
ligands that actually interact with Notch3 in the vessel
in vivo also remain to be identiﬁed.
In summary, we demonstrate for the ﬁrst time, to
our knowledge, that some CADASIL mutations im-
pair the activity of the Notch3 receptor through dis-
tinct mechanisms. Additional studies are needed to
determine whether smooth-muscle cell degeneration
is actually caused by a reduction of Notch3 activity and
to further elucidate the pathogenic effect of the muta-
tions that appear, in this study, to have no effect on the
activity of the receptor.
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